

Ref: 21-457

Freedom of Information Request

20 September 2021

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

We can confirm that we do hold the information you are requesting

Q1. How many patients has your trust treated (for any disease) in the last 6 months with the following treatments:

- Doptelet (avatrombopag) 0
- Jakavi (ruxolitinib) 40
- Nplate (romiplostim) 30
- Revolade (eltrombopag) 25
- Tavlesse (fostamatinib) 0
- Hydroxycarbamide 284

Q2. In the last 6 months, how many patients has your trust treated for:

- Immune thrombocytopenia (ICD10 code D69.3) 257
- Myelofibrosis (ICD10 code D47.4) 167
- Myelofibrosis (ICD10 code D47.4) patients over the age 65 95

Q3. Of the patients treated for immune thrombocytopenia (ICD10 code D69.3) in the last 6 months, how many were treated with:

- Mycophenolate mofetil *
- Rituximab *
- Surgery (splenectomy) 0

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. (Section 40 is the exemption for personal information).

- Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?
- Of the myelofibrosis patients diagnosed in the last 3 years, how many were treated in the past 6 months with Hydroxycarbamide? 6
- Of the myelofibrosis patients diagnosed in the last 3 years, how many have received no active treatment in the past 6 months? 182
- Q5. Does you trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

TREATT: Trial to EvaluAte Tranexamic acid therapy in Thrombocytopenia (35 patients recruited)

Q6. Does you trust participate in any ongoing clinical trials for myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?

No

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance
University Hospitals Bristol and Weston NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the

public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click here.

Yours sincerely

Freedom of Information Team University Hospitals Bristol and Weston NHS Foundation Trust